|2025年6月18日星期三| NO.1和铂、百奥赛图专利纠纷升级 16日,和铂医药对外公布了其核心专利维权行动的最新进展。国家知识产权局于2025年6月5日作出审查决定,维持和铂医药“结合分子”专利权有效,该专利涉及利用转基因动物制备全人源仅重链抗体(HCAb)的方法,而此次决定是针对百奥赛图(北京)医药科技股份有限公司提出的无效宣告请求所作出的。 点评:从此前的行动来看,和铂医药显然将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.